Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 3/20 | 0.62 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2713781 | 1.00 | SLC1A1 (0.62) | SLC1A1TACR1CA1CA2CA7 | |
| SCHEMBL2781638 | 1.00 | SLC1A1 (0.62) | SLC1A1TACR1CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL3901113 | 0.98 | SLC1A1 (0.60) | SLC1A1TACR1CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL16495177 | 0.98 | SLC1A1 (0.60) | SLC1A1TACR1CA1CA2CA7 | |
| SCHEMBL561330 | 0.87 | SLC1A1 (0.73) | SLC1A1TACR1CA1CA2CA7 | |
| SCHEMBL2037281 | 0.87 | SLC1A1 (0.73) | SLC1A1TACR1CA1CA2CA7 | |
| SCHEMBL185608 | 0.87 | SLC1A1 (0.73) | SLC1A1TACR1CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL857896 | 0.86 | SLC1A1 (0.71) | SLC1A1TACR1CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL29350764 | 0.86 | SLC1A1 (0.71) | SLC1A1TACR1CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL9989072 | 0.86 | SLC1A1 (0.71) | SLC1A1TACR1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012398-B2 | Acylated exendin-4 compounds | NOVO NORDISK A/S (DK) | 2015-04-21 | — | — | US | disclosed |
| US-20120283170-A1 | Acylated Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2012-11-08 | — | — | US | disclosed |
| EP-1399431-B1 | NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | disclosed |
| EP-1204652-B1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6649642-B2 | Useful in the treatment of autoimmune and other cathepsin related diseases. | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030087939-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | US | disclosed |
| EP-1204652-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-05-15 | — | — | EP | disclosed |
| US-20010041700-A1 | Novel succinate derivative compounds useful as cysteine protease inhibitors | BEKKALI YOUNES (US) | 2001-11-15 | — | — | US | disclosed |
| US-6313117-B1 | TREATING AUTOIMMUNE DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001009110-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| US-5629285-A | Inhibitors of TNF-α secretion | IMMUNEX CORPORATION (US) | 1997-05-13 | — | — | US | disclosed |
| EP-0715619-A4 | INHIBITORS OF TNF-ALPHA SECRETION | IMMUNEX CORP (US) | 1997-03-19 | — | — | EP | disclosed |
| US-5594106-A | Inhibitors of TNF-α secretion | IMMUNEX CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0715619-A1 | INHIBITORS OF TNF-ALPHA SECRETION | IMMUNEX CORPORATION (US) | 1996-06-12 | — | — | EP | disclosed |
| WO-1995006031-A1 | INHIBITORS OF TNF-ALPHA SECRETION | IMMUNEX CORPORATION (US) | 1995-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | SLC1A1 3349/4885TACR1 592/4885CA1 4129/4885 |
| US-20120283170-A1 | Acylated Exendin-4 Compounds | GLP1R, VIP, IAPP | SLC1A1 960/4885TACR1 1792/4885CA1 3132/4885 |
| US-20010041700-A1 | Novel succinate derivative compounds useful as cysteine protease inhibitors | SDHA, LONP1, SUCNR1 | SLC1A1 1726/4885TACR1 1305/4885CA1 246/4885 |
| US-20030087939-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | SDHA, LONP1, SUCNR1 | SLC1A1 1726/4885TACR1 1305/4885CA1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.